Aventis Pharma: Going strong - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Aventis Pharma: Going strong

Aug 8, 2003

MNC pharma major, Aventis Pharma (formerly Hoechst Marion) has announced its June quarter results recently. The company recorded a 9% increase in the topline and a strong 37% growth in the bottomline. For the first half of FY04 (1HFY04) Aventis registered a 7% increase in revenues and net profits surged by 52%. In this context, let us briefly evaluate the performance of the company.

(Rs m)2QFY032QFY04% Change1HFY031HFY04% Change
Net Sales 1,603 1,753 9.4% 2,981 3,200 7.3%
Other Income 17 40 135.3% 42 68 61.9%
Expenditure 1,343 1,402 4.4% 2,539 2,627 3.5%
Operating Profit (EBDIT) 260 351 35.0% 442 573 29.6%
Operating Profit Margin (%)16.2%20.0% 14.8%17.9%
Interest 1 - -100.0% 3 - -
Depreciation 37 40 8.1% 75 80 6.7%
Profit before Tax 239 351 46.9% 406 561 38.2%
Extraordinary Items 18 (5)- 1 60 -
Tax 87 113 29.9% 130 199 53.1%
Profit after Tax/(Loss) 170 233 37.1% 277 422 52.3%
Net profit margin (%)10.6%13.3% 9.3%13.2% 
No. of Shares (eoy) (m) 23.0 23.0   23.0 23.0  
Diluted Earnings per share*29.540.5 24.136.6 
P/E (at current price) 10.6    11.7  
* annualised      

If we exclude extraordinary item, bottomline growth in the June quarter surges to 57% YoY. If we do the same for the half yearly result, bottomline growth stands at over 31%. This indicates that the June quarter has operationally been much better than the company’s March quarter.

For 2QFY04, Aventis has recorded a steady growth in the topline. While the domestic revenues grew by 8.5%, exports registered a 12% rise. The company’s strategic brands grew by a strong 17%. Aventis’s strong brand equity and secondary demand for its brands like Cardace (27% rise), Targocid (24%), Clexane (23%), Amaryl (20%) & Allegra (17%) were the key reasons for this strong growth. However, the revenues from ‘Tavanic’ have seen a steady decline (26% drop). Consequently, the company has gradually reduced its investments in this brand. Among other brands, Combiflam (27%), Rabipur (20%), and Trental (36%) continued to maintain leadership position in their respective segments. While, Avil and Daonil registered single-digit growths, Soframycin recorded negative growth, but remained leader in its category.

A favourable domestic product mix coupled with an increase in the contribution from exports has helped Aventis improve its operating margins. Improvement in operating efficiencies and a sharp increase in the other income has helped Aventis record an increase in the net margins.

In July ’03, Aventis has launched Lantus, an insulin glargine used for the treatment of diabetes. The product has been already launched in Germany and USA. The company is in the process of obtaining regulatory clearance for launching this product in India. Actonel, a product for osteoporosis, has also been successfully introduced in many countries and the company is likely to take a decision on its launch in India soon. The launch of these products could benefit from APL’s brand name and franchise network. This could further improve the performance of the company.

At Rs 429 the Aventis stock trades at a P/E of 11.7x its annualised 1HFY04 earnings. Historically, the stock has traded at a discount to its MNC peers owing to some Indian promoter related issues. Considering the relatively new product portfolio, high exposure in the lifestyle segments and strong parent product pipeline, the long-term prospects of the company seem bright.

Equitymaster requests your view! Post a comment on "Aventis Pharma: Going strong". Click here!

  

More Views on News

SANOFI INDIA 2019-20 Annual Report Analysis (Annual Result Update)

Oct 25, 2021 | Updated on Oct 25, 2021

Here's an analysis of the annual report of SANOFI INDIA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

How to Hit Rs 100 Crore Wealth in Your Lifetime (Equitymaster Wealth)

Nov 15, 2021

This is how you can achieve the ambitious goal of a net worth of Rs 100 crore.

Don't Sell these Stocks if the Market Falls (Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Nov 26, 2021 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - ADCOCK INGRAM COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS